Pharmacodynamics and Systemic Exposure of Esomeprazole in Preterm Infants and Term Neonates with Gastroesophageal Reflux Disease

Omari, Taher; Lundborg, Per; Sandström, Marie; Bondarov, Patrik; Fjellman, Mia; Haslam, Ross; Davidson, Geoffrey P.

doi:10.1016/j.jpeds.2009.02.025

Cited by 46 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of the MII-pH device recording simultaneously in at least 6 different esophageal sites, it provides the ability to identify and characterize the bolus-events of GER, their length of time, approximate extension and their association with any symptom [9].…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the Accuracy of Computer Automated Analysis of Esophageal 24- hour Impedance pH Studies

Sabouni¹,

Ghalayini²,

Bala³

et al. 2017

J Gastrointest Dig Syst

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of the Accuracy of Computer Automated Analysis of Esophageal 24- hour Impedance pH Studies

Sabouni¹,

Ghalayini²,

Bala³

et al. 2017

J Gastrointest Dig Syst

View full text Add to dashboard Cite

show abstract

“…[10]. Between 2004-2008 PPI prescriptions for newborns less than 1 month of age rose more than 2 fold from 0.07% to 0.17%-from a data base of 5000 which represents on average 0.13% of babies born [11]. This incidence equates to the lower range of the incidence of PS.…”

Section: Introductionmentioning

confidence: 99%

“…In 2011 the FDA legalized intra-venous esomeprazole for new-borns This is likely to further increase PPI usage. The duration of therapy is not defined [11,12]. Vomiting or regurgitating infants will be unlikely to have escaped this treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Babies with PS also suffer from GERD with occasionally produces erosive acid induced reflux oesophagitis. It is of interest to also observe that in only 10% of pediatric patients is the diagnosis of GORD confirmed [11]. What are we to make of this juxtaposition of decline in the incidence of PS and the rise in PPI prescriptions in the neonatal period?…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pyloric Stenosis of Infancy and Newborn Prescription of PPI Drugs-The Acid Test

Im¹

2017

JPNC

View full text Add to dashboard Cite

There is mounting evidence that the inheritance of Primary Hyperacidity coupled with the normal developmental increase of acid production at around 3 weeks of age, produces sufficient peak hyperacidity to trigger repeated contractions of the pyloric sphincter and work hypertrophy. Since this peak acidity is temporary and naturally resolves, any stimulus which reduces acidity even temporarily during these critical 3-4 weeks would theoretically lead to a long term cure and reduce the incidence of PS. During the last 3 decades PPI drugs have been increasingly used in modern pediatric practice in the Western world.In new-borns less than 1/12 of age PPI prescriptions have more than doubled between 2004 and 2008. usually for an alleged diagnosis of GERD. During the last 2 decades there has been a significant, unusual and uniform decline in the incidence of PS in the western world. The demographics of the decline give no support to the proposal that the back to sleep campaign for Sudden Infant Death Syndrome (SIDS) is the explanation. It is here asserted that the falling incidence of PS is caused by PPI induced loss of acidity at a critical time in the evolution of the disease process.

show abstract

“…In the battery of tests were pharmacokinetic (PK) and pharmacodynamic (PD) studies conducted in part to establish appropriate doses. Results from studies of various available PPIs in infants aged \1 year, including preterm infants and neonates, are currently being reported [14][15][16][17][18], and some efficacy studies have also been reported [19,20].…”

Section: Introductionmentioning

confidence: 99%

Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease

et al. 2010

View full text Add to dashboard Cite

show abstract

Pharmacodynamics and Systemic Exposure of Esomeprazole in Preterm Infants and Term Neonates with Gastroesophageal Reflux Disease

Cited by 46 publications

References 26 publications

Evaluation of the Accuracy of Computer Automated Analysis of Esophageal 24- hour Impedance pH Studies

Evaluation of the Accuracy of Computer Automated Analysis of Esophageal 24- hour Impedance pH Studies

Pyloric Stenosis of Infancy and Newborn Prescription of PPI Drugs-The Acid Test

Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About